2019年08月06日
Xueming Qian outlines the new company’s origins, the space it seeks to fill within the highly competitive Chinese oncology market, and where Chinese biotech stands globally in 2019
“I did not want to work on an antibody similar to the dozens already in clinical trials, I wanted to find a differentiator!”
